CMV pp65 tetramer is a classic tool for quantitative monitoring of human cytomegalovirus-specific CD8⁺ T cell responses
This article centers on the CMV pp65 tetramer, beginning with the immunological significance of the human cytomegalovirus pp65 antigen, reviewing the identification and validation process of its dominant CTL epitope QYDPVAALF, elaborating the molecular construction principles of tetramer technology, and summarizing the application value of this tool in scenarios such as transplant immune monitoring and adoptive cell therapy, thereby providing a reference for researchers in the fields of viral immunology and cell therapy.
- Recent Advances
- Product Information
Recent Advances
CMV pp65 Tetramer Is a Classic Tool for Quantitative Monitoring of Human Cytomegalovirus-Specific CD8⁺ T Cell Responses
Summary: Taking the CMV pp65 tetramer as its main thread, this article begins with the immunological status of the human cytomegalovirus pp65 antigen, reviews the identification and validation of its dominant CTL epitope QYDPVAALF, explains the molecular construction principle of tetramer technology, and summarizes the application value of this tool in scenarios such as transplant immune monitoring and adoptive cell therapy, providing a reference for researchers in viral immunology and cell therapy.
I. Human Cytomegalovirus pp65 Is the Core Target Antigen of CMV-Specific Cellular Immune Responses
Human cytomegalovirus (CMV) is a β-herpesvirus widely disseminated in the population. Infection in healthy individuals is usually latent, but in immunocompromised populations such as hematopoietic stem cell transplant and solid organ transplant recipients, viral reactivation can cause serious complications such as interstitial pneumonia and gastroenteritis, directly threatening patient prognosis. Among the more than two hundred proteins encoded by the CMV genome, the 65 kDa lower matrix phosphoprotein pp65 (UL83) has become the most important recognition target of CMV-specific cytotoxic T lymphocyte (CTL) responses because it is expressed early and at high abundance during the viral replication cycle and can be processed and presented without de novo viral protein synthesis. Numerous studies have shown that T cell responses against pp65 occupy a dominant position in CMV immune protection, and this feature has laid a clear biological foundation for establishing pp65-targeted T cell detection systems.

II. The QYDPVAALF Epitope Was Identified and Fully Validated in the HLA‑A*24:02 Context
T cells can only recognize antigenic peptides presented by self-MHC molecules, so pp65-specific detection must be tied to a specific HLA allele. Kuzushima et al. reported in Blood in 2001 that, through multiple screening by computer-assisted algorithm prediction, MHC stabilization assays, and enzyme-linked immunospot (ELISPOT) assays, they identified from 83 candidate peptides the dominant CTL epitope QYDPVAALF presented by the HLA‑A*24:02 molecule, corresponding to amino acids 341 to 349 of the pp65 protein. Because the carrier frequency of HLA‑A*24:02 in East Asian populations (such as Chinese and Japanese) is significantly higher than in European and American populations, this epitope has special applicable value for CMV immunology research in Asian populations. Subsequent studies confirmed that the endogenous processing and presentation of this epitope are well defined; in the peripheral blood of HLA‑A24-positive and CMV-seropositive healthy donors, CD8⁺ T cells specifically recognizing this peptide accounted for 0.04% to 0.27% of total CD8⁺ T cells, indicating that in the HLA‑A*24:02 context, CMV-specific CTL responses are highly concentrated on this pp65 epitope, making QYDPVAALF an ideal peptide for constructing the pp65 tetramer.
III. The pp65 Tetramer Brings the Detection of Antigen-Specific T Cells into the Era of Direct Quantification
Tetramer technology was established by Altman et al. in 1996, and its core idea is to overcome the bottleneck of low-affinity recognition through multivalent binding: peptide-MHC (pMHC) monomers formed by in vitro refolding are biotinylated at the BirA substrate peptide site fused to the C-terminus of the heavy chain, and then bind to fluorophore-conjugated streptavidin at a molar ratio of 4:1 to form tetramers carrying four pMHC complexes. Because the affinity between a single pMHC and the T cell receptor (TCR) is low and dissociation is fast, the multivalent binding of the tetramer significantly improves binding affinity and stability, enabling flow cytometry to directly stain, count, and phenotype live antigen-specific CD8⁺ T cells. Compared with methods that rely on functional responses such as ELISPOT and intracellular cytokine staining, tetramer staining requires no in vitro stimulation or culture expansion, can directly detect freshly isolated peripheral blood mononuclear cells, and can be combined with markers such as CD27, CD45RA, and CCR7 for multicolor subsetting. The allophycocyanin (APC)-labeled pp65 tetramer has high fluorescence intensity and good photostability, making it particularly suitable for incorporation into routine multicolor flow cytometry panels.
IV. The CMV pp65 Tetramer Has Reliable Application Evidence in Both Basic Research and Clinical Immune Monitoring
At the methodological validation level, domestic researchers systematically optimized the expression in Escherichia coli and in vitro refolding system of the HLA‑A*24:02 heavy chain, successfully prepared tetramers loaded with the QYDPVAALF peptide, and detected tetramer-positive CTLs accounting for 0.09% to 0.37% of CD8⁺ T cells, confirming that this reagent is suitable for CMV immunology research in the Chinese population. At the functional correlation level, Japanese scholars used HLA‑A*24:02/pp65 tetramers to stain CTL lines induced by peptide stimulation and found that the frequency of tetramer-positive cells was significantly correlated with interferon‑γ (IFN‑γ) production (r = 0.943, P < 0.001), suggesting that tetramer staining can serve as a reliable surrogate indicator of T cell function. At the clinical scenario level, CMV reactivation is one of the major post-transplant complications; dynamic monitoring of frequency changes in pp65-specific CTLs in peripheral blood can provide an objective laboratory basis for judging infection risk, timing antiviral intervention, and evaluating immune reconstitution after adoptive CTL infusion.
Conclusion
With the construction logic of "pp65 dominant epitope—HLA‑A*24:02 presentation—biotinylated monomer—streptavidin tetramerization," the CMV pp65 tetramer transforms viral-specific T cell responses that could only be indirectly inferred through functional experiments into a target population that can be directly gated, counted, and subsetted on flow cytometry plots; the QYDPVAALF (pp65 341–349) epitope, independently identified and repeatedly validated in the HLA‑A*24:02 context with high carrier frequency in East Asia, further endows this tool with clear biological specificity. Around this direction, UAi provides UA‑MHC HLA‑A*24:02/QYDPVAALF CMV pp65 Tetramer‑APC Labelled, offering reliable support for quantitative monitoring of CMV-specific CD8⁺ T cells, post-transplant immune risk assessment, and adoptive cell therapy research, and will continue to facilitate in-depth exploration in the fields of viral immunology and cellular immunotherapy.
Product Information






